Repair & Recovery
BPC-157 / KPV / TB-500 Injection (Repair & Recovery Stack)
A three-peptide injection combining BPC-157, KPV and TB-500 — designed for patients whose providers want to address tissue repair, inflammation and mobility together in one protocol.
This is a compounded preparation made by a licensed pharmacy. It is not FDA-approved, and it is prescribed only when a licensed provider determines it is appropriate for you.
Already know this is what you want? The second option books the appointment straight away. Not sure yet? See the labs first.
Your consult is free. We will not prescribe this, or anything, before a clinician has spoken with you. Final cost depends on the form and dose prescribed.
Mechanism
Repair, calm, and recover.
This formulation adds KPV, a tripeptide studied for anti-inflammatory signaling, to the BPC-157 and TB-500 combination. The three peptides act through distinct pathways — tissue repair, localized inflammation, and cell migration.
Providers typically reserve this three-peptide combination for patients with more complex or multi-site recovery needs rather than a single, isolated injury.
Like the other formulations in this line, it's intended as a time-limited cycle rather than an indefinite daily therapy.
Protocol
How treatment usually runs.
A typical schedule. Yours is set by your clinician, and adjusted as you go.
| Phase | Weeks | Typical | Purpose |
|---|---|---|---|
| Start | 1–2 | Low combined dose once daily | Subcutaneous injection; rotate sites. |
| Build | 3–6 | Standard combined dose | Once daily or as directed by your provider. |
| Taper / Reassess | 7–8 | Continued or tapered | Reviewed with your provider around 6–8 weeks. |
What to expect
Honestly, over time.
Early response
Some patients report early changes in comfort.
Continued recovery
Response is gradual and varies by individual and condition.
Cycle review
Your provider determines whether to continue, adjust or pause.
Evidence
What the research shows.
Each peptide in this combination has been studied mainly in preclinical or small, early-stage settings; there is no large controlled human trial establishing the efficacy of this three-peptide combination specifically. Reported benefits are largely anecdotal.
Results vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity.
Safety and eligibility
Your consult and labs screen for all of the following.
- Do not use if you have a history of cancer or active malignancy — BPC-157 and TB-500 are studied in contexts involving tissue and vascular growth, a serious consideration for anyone with a cancer history; review this with your provider before starting.
- Tell your provider about autoimmune disease, pregnancy, and any other injectable therapies you're currently using.
- Common side effects include injection-site reaction, mild fatigue and headache.
- Not FDA-approved for this use — prescribed at your provider's discretion.
FAQ
BPC-157 / KPV / TB-500 Injection (Repair & Recovery Stack) questions.
KPV is a tripeptide studied for its potential role in calming localized inflammation, which is why it's paired here with two peptides studied for tissue repair and mobility.
Providers generally reserve this three-peptide protocol for patients with more complex recovery needs rather than a single, isolated injury.
No. BPC-157 and TB-500 are studied in contexts involving tissue and blood vessel growth, so a cancer history is a serious factor your provider must review before prescribing.
Related
Often part of the same plan.
BPC-157 Injection
Subcutaneous injection
BPC-157 + TB-500 Injection (Wolverine Stack)
Subcutaneous injection
